Get started

Moderna

Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach. Navigating the COVID-19 Landscape: While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap. Looking Beyond COVID: Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories. International Endeavors: Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions. Charting the Course Ahead: As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead. Conclusion: Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
NASDAQ:MRNALong
by DEXWireNews
Moderna Break of Major Support, Short PotentialThis is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe. Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone. We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay above the "MAJOR RESISTANCE" line. Though the CURRENT candle has not yet closed, which it will end of trading session Monday, the 7th of August. This in my opinion is a critical development. If we CONFIRM below this $115 ish area, the lower range of about $82.00 of the ORANGE zone becomes more likely. The ORANGE zone, or price range between $115 and $82 has barely any market structure or in other words barely any candles. It would be easy for price to fall stright down, in my opinion. This can be an area to take a SHORT position. Another thing to notice since the BLOW of top, we have been forming a DESCENDING TRIANGLE. Its been forming since August 2021, this is NO JOKE. Measuring the target of the end point of descending triangle we get about a 75% drop target. Just remember it doesnt have to play out exactly but its something to consider and keep in the back of the mind. So just to mention: 1st Target = $82 ish area 2nd Target = $57- $47 range Last Target = Descending triangle measured target of $29 ( *Less likely for the time being) RSI has been: 1. printing Lower Highs 2. is currently below the Black Moving average, which i use as an indication of price moving down 3.Is currently in process of ALL TIME RSI LOW, provided we close this weeks candle at current RSI lvl. STOCH RSI -> Setting up for a BEARish cross. This if it occurs and we are below the MAJOR SUPPORT, bearish momentum can push price down. Lastly ADX & DI -> We have RED line cross above Green and pointing up. We need to observe this, this indicates also the BEARISH momentum is coming in. If the BLACK moving average curves up and starts moving towards the RED/GREEN line with RED being on top, this will indicate bearish momentum. CONCLUSION: We are at major cross roads for MRNA. If we don't have any buying occur during Mondays trading session, and we close below MAJOR SUPPORT, it may be time to SHORT MRNA. We have not had any luck trying to break and stay above the "MAJOR RESISTANCE" line. This, along with multiple touches on MAJOR SUPPORT, has made this WEAK (in my opinion). Short targets include the primary, secondary and descending triangle target levels. Indicators are also shaping up to support the current price action. At times like this, it is important to observe further clues of bearish activity, to be patient and take it one step at a time. Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again. If you have any questions, do reach out. Thank you again. DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. When trading always spend majority of your time on risk management strategy.
NASDAQ:MRNAShort
by SafofAllTrades
$MRNA What Up$MRNA started playing this since it was in the low $20s and then got rid of it at the start of this year. And IMO this is headed under $100. It will get a kick start when the next Pandemic happens and WHO rules lockdowns across the world. Regardless of the hype, I don't see any reason to take a position in this ticker. The only outcome is, EXIT for me :) Although it does have a promising technology but it will not be able to generate the kind of revenue it did with the Pandemic vax
NASDAQ:MRNAShort
by VIN786
Bullish Crossover for MRNA Share Appears in the HorizonModerna's share (MRNA) price has been running in a narrow price range since November 8 after a series of gains extending since October 21, surpassing the short and long-term exponential moving averages in a positive short-term sign. Meanwhile, an unclear zigzag path has dominated MRNA share since the beginning of the year. As for now, and on the daily chart, we keep an eye on 180.13 and $198.82 as possible bullish targets, as we await the bullish crossover of the MA-25 and MA-50 to achieve the possible bullish path. On the flip side, if MRNA share price fails to stabilize above the $162 level, the previous bullish hypothesis may be invalidated, and we may witness a pullback towards $142-135 levels (yellow shaded area).
NASDAQ:MRNALong
by SamerHa
MRNA being a good market sell?Moderna - 30d expiry - We look to Sell at 186.88 (stop at 198.38) Price action continued to range between key support & resistance (120 - 190) and we expect this to continue. Daily signals are mildly bearish. Posted a Double Top formation. An Evening Doji Star formation has been posted at the high. We look for a temporary move higher. Offers ample risk/reward to sell at the market. Our profit targets will be 158.11 and 150.11 Resistance: 190.00 / 197.44 / 210.00 Support: 180.00 / 170.00 / 160.00 Daily chart Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
1
Moderna, Inc. Flashes Bearish SignalsWe have a lower high, compare this past 16-November to 4-August. We also have a clear bearish pattern in the form of a rising wedge. Going by the candlesticks, we can spot some bearish signals there as well. 16-Nov. Doji is a bearish candle. 18-Nov. another bearish candle, confirmation of the previous one. Today we gapped lower which gives strength to the bears. A correction can easily form here. CHANGE MRNA needs to break and close above 188.65 for the bullish momentum to resume. Trading below 185 spells doom. Support levels/targets are marked in light blue. Namaste.
NASDAQ:MRNAShort
by MasterAnanda
1
MODERNA has most likely bottomedModerna Inc (MRNA), a much discussed stock over the previous years, is having a +8% day, a very encouraging since following the rejection on the 1D MA50 (blue trend-line) three days ago. What's more interesting is that we have seen almost the same pattern in the stock's all time lows in 2019. As you see, the price since September has been on Lower Lows while the 1D RSI has been on Higher Lows, indicating a Bullish Divergence that is often seen on market bottoms before the price reverses. The very same Bullish Divergence was spotted from June 25 2019 until August 07 2019. It was also a remarkable 1D candle of +20% back then that signaled the sentiment shift. The price confirmed those bias when it broke above the 1D MA50. The break of the 1D MA200 (orange trend-line) a few days later opened the way for an incredible two year rise that was of course dominated by the COVID fundamentals mostly. It is worth noting that at the moment the 1D MA200 is too close to the 1D MA50 as opposed to 2019, so best to have our mark on the 1W MA100 (green trend-line) which has rejected both of 2022 uptrends in March 21 and August 04. It is exactly now where the 200.00 Resistance is (formed by the August 04 High). Also notice that the 1W MA200 (red trend-line) has made its appearance in October for the first time in history and provided the necessary Support for the early October push. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:MRNALong
by TradingShot
Moderna at key resistance? Moderna Short Term We look to Sell at 183.71 (stop at 203.39) Preferred trade is to sell into rallies. Previous resistance located at 190.00. Trading within a Bearish Channel formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 121.74 and 94.19 Resistance: 190.00 / 220.00 / 495.00 Support: 156.00 / 120.00 / 100.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Shooting Star on Moderna? Moderna Short Term We look to Sell at 146.42 (stop at 154.23) Preferred trade is to sell into rallies. Price action has posted a bearish Shooting Star and is negative for short-term sentiment. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 122.21 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 120.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year) Its Financial Health is very strong. Why not wait till Moderna makes greater progress and finds It Resistance Again at $450 Moderna has many projects running. So if we see progress in some of the projects in the next Years, we will see a great price rise. I believe it won't be difficult to reach its older resistance again, around $450. Disclaimer: Just my Idea! Find your Trading Ideas and learn and study more!
NASDAQ:MRNALong
by TraderMentorX
Feeling sick? (Moderna)Moderna Short Term We look to Sell at 133.52 (stop at 141.88) Preferred trade is to sell into rallies. Prices expected to stall near trend line resistance. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 105.41 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 116.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Moderna in trouble? Moderna Short Term - We look to Sell at 149.49 (stop at 160.31) Preferred trade is to sell into rallies. Closed below the 20-day EMA. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade. Our profit targets will be 123.84 and 103.50 Resistance: 150.00 / 171.76 / 187.50 Support: 125.00 / 120.00 / 104.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
2
Pharma firm SIGA cashes in on monkeypox scareNew York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health Organization declared that vaccines used against smallpox — before the virus was eradicated in 1980 — can be used to fight monkeypox. SIGA already won approval from the US Food and Drug Administration in 2018 to distribute its oral TPOXX capsules as a treatment against smallpox even when there were no reports of confirmed or possible cases of smallpox at the time. US advances in vaccine orders Most recently, SIGA on Thursday secured another approval from the FDA for the intravenous (IV) formulation of TPOXX for patients who are unable to swallow the drug’s oral variant. SIGA said the IV formulation of TPOXX has already been cited in the recent US president’s budget request to treat a patient with monkeypox in the US. The company's shares surged 43% on Friday before paring gains to close 13% lower on the Nasdaq on Monday, and another 15.5% on Tuesday. SIGA stock remains up 26.5% over the past 5 days of trading. SIGA also stands to benefit from TPOXX’s use in Canada and Europe, where cases of moneypox were detected in recent weeks. Europe has already approved the use of TPOXX against monkeypox, cowpox, and complications from immunization with vaccinia, the company said. Growing monkeypox threat Monkeypox, first discovered in 1958, is a viral illness that first occurred in colonies of monkeys. The first human case of the virus was recorded in the Democratic Republic of Congo in 1970, according to the US Centers for Disease Control and Prevention. The virus can cause symptoms like fever, body aches, swollen lymph nodes and bumpy rashes. Cases of monkeypox have so far been reported in at least 17 countries including the US, Canada, the UK, Spain, Portugal, France, Italy and Australia. Big pharma steps in SIGA and another vaccine maker in Denmark, Bavarian Nordic (CPH:BAVA), have kept samples of smallpox virus for research purposes in case of biological warfare. The emergence of monkeypox this year prompted both companies to start mass producing vaccines against smallpox to offer protection against monkeypox. CDC officials on Monday said the US is in the process of releasing Bavarian Nordic’s Jynneos vaccine doses to fight against monkeypox. The US has stockpiled more than 1,000 doses of the vaccine and CDC officials expect to boost their purchases in the coming weeks. Bavarian Nordic’s shares on the Nasdaq Copenhagen surged to a four-month high on Monday. The Danish company on May 18 said the US government has already placed a $119 million order for the production of freeze-dried Jynneos vaccines, although deliveries are not expected until 2023 and 2024. Meanwhile, Moderna (NASDAQ:MRNA), which succeeded in developing vaccines against COVID-19, also started testing vaccines against monkeypox. The company on Tuesday said it is investigating potential vaccines against monkeypox in pre-clinical trials. No urgent need for mass vaccinations Although vaccines against monkeypox are already within reach just weeks into reports of an outbreak emerged, some experts and WHO officials say inoculations against monkeypox will not likely involve a mass campaign as the virus, unlike COVID-19, is not as contagious. Vaccinations would likely be focused only on people with close contact with infected individuals. "If a case is reported in the country, a public health SWAT team goes out, finds out who the close contacts are of that first case, and vaccinates just those close contacts, and not the entire city or suburb,” Dr. David Freedman, professor emeritus of infectious diseases at the University of Alabama, was quoted by Time magazine as saying.
NASDAQ:SIGA
by BlackBull_Markets